About Moderna
Moderna is a company based in Cambridge (United States) founded in 2010 by Robert S Langer, Kenneth R Chien, and Timothy A Springer. It operates as a HealthTech. Moderna has raised $2.78 billion across 21 funding rounds from investors including Merck, Fidelity Investments and Astrazeneca. The company has 5,800 employees as of December 31, 2024. Moderna has completed 1 acquisition, including OriCiro Genomics. Moderna offers products and services including mRNA Medicines. Moderna operates in a competitive market with competitors including BridgeBio, Adaptive Biotechnologies, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 5800 as on 31 Dec, 2024
- Founders Robert S Langer, Kenneth R Chien, Timothy A Springer
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Moderna, Inc.
-
Annual Revenue
$3.24 B (USD)-52.69as on Dec 31, 2024
-
Net Profit
-$3.56 B (USD)24.46as on Dec 31, 2024
-
EBITDA
-$3.76 B (USD)-3.59as on Dec 31, 2024
-
Total Equity Funding
$2.78 B (USD)
in 21 rounds
-
Latest Funding Round
$590 M (USD), Grant
Jan 17, 2025
-
Investors
Merck
& 21 more
-
Employee Count
5800
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Moderna
Moderna is a publicly listed company on the NASDAQ with ticker symbol MRNA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Moderna
Moderna offers a comprehensive portfolio of products and services, including mRNA Medicines.
mRNA medicines are developed to fight various diseases.
People of Moderna
Unlock access to complete
Unlock access to complete
Software Development Team
237 people
Leadership Team
139 people
Senior Team
69 people
Product Management Team
68 people
Operations Team
50 people
Principal Team
36 people
Data Analysis and Operations Team
34 people
Finance and Accounting
21 people
Unlock access to complete
Funding Insights of Moderna
Moderna has successfully raised a total of $2.78B across 21 strategic funding rounds. The most recent funding activity was a Grant round of $590 million completed in January 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Moderna
Moderna has secured backing from 22 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Fidelity Investments and Astrazeneca.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
PE firm investing in Asia and Europe
|
Locked | Locked | Locked | |
|
Sequoia Capital is engaged in venture capital investments.
|
Locked | Locked | Locked | |
|
Private investment firm focused on multiple sectors
|
Locked | Locked | Locked |
Investor details for Moderna
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Moderna
Moderna has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include OriCiro Genomics.
Investment portfolio details for Moderna
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Technologies for DNA synthesis and amplification are developed.
|
Locked | Locked | 2018 | Locked |
Complete acquisition details for Moderna
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Moderna
Detailed financials for Moderna
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Moderna Comparisons
Peer comparison for Moderna
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Moderna
Moderna operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Adaptive Biotechnologies, Spark Therapeutics, Rhythm Pharmaceuticals and Horizon Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Moderna
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Moderna
Complete news archive for Moderna
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Moderna
Moderna was founded in 2010 and raised its 1st funding round 2 years after it was founded.
Moderna is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Moderna is a funded company, having raised a total of $2.78B across 21 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Moderna is 5,800.
Annual revenue of Moderna is $3.24B as on Dec 31, 2024.
Moderna is engaged in pioneering mRNA technology to create medicines that combat diseases by instructing cells to produce necessary proteins. The company operates in the biotechnology sector, targeting a wide range of conditions, including those with no current treatments. Solutions are designed to be accessible, free of animal products or preservatives, and are developed rapidly through a unique platform that allows multiple mRNA designs to be tested efficiently. Efforts are made to deliver impactful health solutions globally.
Moderna's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Moderna offers mRNA Medicines.
Yes, Moderna is publicly traded on NASDAQ under the ticker symbol MRNA.
Moderna has made 1 acquisition, including OriCiro Genomics.
Moderna has 22 investors. Key investors include Merck, Fidelity Investments, Astrazeneca, Alexion, and Julius Baer.
The ticker symbol of Moderna is MRNA on NASDAQ.